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Abstract
BACKGROUND—Family history is a significant risk factor for prostate cancer, although the
molecular basis for this association is poorly understood. Linkage studies have implicated
chromosome 17q21-22 as a possible location of a prostate-cancer susceptibility gene.
METHODS—We screened more than 200 genes in the 17q21-22 region by sequencing germline
DNA from 94 unrelated patients with prostate cancer from families selected for linkage to the
candidate region. We tested family members, additional case subjects, and control subjects to
characterize the frequency of the identified mutations.
RESULTS—Probands from four families were discovered to have a rare but recurrent mutation
(G84E) in HOXB13 (rs138213197), a homeobox transcription factor gene that is important in
prostate development. All 18 men with prostate cancer and available DNA in these four families
carried the mutation. The carrier rate of the G84E mutation was increased by a factor of
approximately 20 in 5083 unrelated subjects of European descent who had prostate cancer, with
the mutation found in 72 subjects (1.4%), as compared with 1 in 1401 control subjects (0.1%) (P =
8.5×10−7). The mutation was significantly more common in men with early-onset, familial
prostate cancer (3.1%) than in those with late-onset, nonfamilial prostate cancer (0.6%) (P =
2.0×10−6).
CONCLUSIONS—The novel HOXB13 G84E variant is associated with a significantly increased
risk of hereditary prostate cancer. Although the variant accounts for a small fraction of all prostate
cancers, this finding has implications for prostate-cancer risk assessment and may provide new
mechanistic insights into this common cancer. (Funded by the National Institutes of Health and
others.)
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PROSTATE CANCER IS THE MOST COMMON noncutaneous cancer diagnosed in men in the United States, with
more than 240,000 new cases expected in 2011.1 Despite the demonstration of a strong
familial component, identification of the genetic basis for hereditary prostate cancer has
been challenging. Linkage studies of families with hereditary prostate cancer have provided
inconsistent results.2 In contrast, genome-wide association studies have led to the
identification of more than 30 single-nucleotide polymorphisms (SNPs) that are consistently
associated with prostate cancer.3 However, the magnitude of risk elevation attributed to each
individual SNP is low, with an increased elevation in risk by a factor of less than 1.3, and
these SNPs in aggregate account for only an estimated one quarter of familial risk.4
One of the most intensely investigated regions of the genome for prostate cancer
susceptibility loci is chromosome 17q21-22. Prostate-cancer linkage to this region was
initially reported by the University of Michigan Prostate Cancer Genetics Project on the
basis of analysis of 175 pedigrees of families with hereditary prostate cancer.5 Several
collaborative studies that included families in the Prostate Cancer Genetics Project,
including a large study by the International Consortium for Prostate Cancer Genetics, also
showed evidence of linkage to 17q21-22.6,7 We performed a fine-mapping study of this
region using 453 pedigrees from the Prostate Cancer Genetics Project and Johns Hopkins
University. A subset of 147 families with 4 or more confirmed affected men and an average
age at diagnosis of prostate cancer of 65 years or less provided strong evidence for linkage
(logarithm of odds [LOD] near marker D17S1820, 5.49) and a narrow candidate interval for
a putative susceptibility gene (1-LOD support interval, approximately 10 cM).8
Next-generation sequencing technologies have provided new opportunities to interrogate
large genomic intervals that are implicated in human disease in a rapid and comprehensive
manner. Given the consistent evidence of prostate-cancer linkage to 17q21-22 markers in
our multiplex families with hereditary prostate cancer, we designed a targeted sequencing
strategy to analyze 2009 exons of 202 genes contained in the most likely genomic interval
defined by our fine-mapping studies.
METHODS
STUDY SUBJECTS
For data from the Prostate Cancer Genetics Project, subjects were restricted to men with
prostate cancer who had at least one living first- or second-degree relative who also had
prostate cancer or those in whom prostate cancer had been diagnosed at an age of 55 years
or less, regardless of family history. We confirmed the diagnosis of prostate cancer by
reviewing medical records whenever possible. Ancestry was self-reported. All subjects
provided written informed consent to participate in the study. The protocol and consent
documents were approved by the institutional review board at the University of Michigan
Medical School.
For data from Johns Hopkins University, families with hereditary prostate cancer each had
at least three first-degree relatives with prostate cancer. We verified the diagnosis of prostate
cancer by reviewing medical records. Included in the study were men who had undergone
radical prostatectomy for the treatment of clinically localized prostate cancer at Johns
Hopkins Hospital. Advanced prostate cancer was defined as biochemical recurrence of
prostate cancer or metastatic or castration-resistant disease that was identified at the Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. The average age at
diagnosis in this latter group was 60.9 years.
Control subjects for this study included men who had undergone screening for prostate
cancer. Such screening included measurement of serum prostate-specific antigen levels and
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digital rectal examination at Johns Hopkins Hospital, Johns Hopkins Bayview Medical
Center, Johns Hopkins University Applied Physics Laboratory, and several other locations
in the mid-Atlantic area. Inclusion criteria for control subjects included a knowledge of
ancestry and no diagnosis of prostate cancer. For all studies at Johns Hopkins University,
research proposals were reviewed and approved by the institutional review board.
TARGETED SEQUENCING OF GENES IN CANDIDATE REGION
We selected the youngest patient with prostate cancer who had available DNA from 94
families (54 families from the Prostate Cancer Genetics Project and 40 from Johns Hopkins
University) on the basis of evidence of 17q21-22 linkage. Seven of the families were of
African descent, 2 were of Asian descent, and the remaining 85 were of European descent.
We identified 202 genes in our genetic region of interest (approximately 15.5 Mb).8 Details
of sequence analysis are provided in the Supplementary Appendix, which is available with
the full text of this article at NEJM.org.
GENOTYPING OF HOXB13 VARIANTS
We genotyped variants of HOXB13, a gene encoding transcription factor homeobox B13,
which is within our candidate interval, using the MassARRAY system (Sequenom) and
TaqMan assays (Applied Biosystems/Life Technologies). We confirmed all variants found
on either of these platforms using Sanger sequencing.
STATISTICAL ANALYSIS
We performed association analyses for the HOXB13 G84E variant using Fisher’s exact tests
and linear regression models implemented in the statistical program R (http://cran.r-
project.org). We included genotype data for 5083 unrelated men in whom prostate cancer
had been diagnosed and for 1401 unrelated men who were presumed to be free of prostate
cancer. These subjects were not part of the discovery sequencing study and were of self-
reported European descent. Additional case–control association analyses for G84E included
the use of publicly available data for 1233 subjects of European descent from the Exome
Sequencing Project,9 funded by the National Heart, Lung, and Blood Institute, and 28
unrelated genotyped samples from the Centre d’Etude du Polymorphisme Humain from
Utah (CEU) HapMap.10 We tested the association between HOXB13 G84E and two
quantitative clinical variables: the age at diagnosis and Gleason grade.
RESULTS
TARGETED SEQUENCING OF 202 CANDIDATE GENES
We reviewed all sequence data for the presence of nonsense or missense mutations in 202
genes in our genetic region of interest.8 Probands from four families were observed to have
the same nonsynonymous mutation in HOXB13, a change of adenosine for guanine
(transition, c.251G→A) in the second position of codon 84 (GGA→GAA), resulting in a
nonconservative substitution of glutamic acid for glycine (G84E) (see Table 1 in the
Supplementary Appendix for complete sequencing results). At the time of this analysis, this
mutation, now identified as rs138213197, was not reported in dbSNP, the database of known
DNA sequence variants of the National Center for Biotechnology Information (NCBI), nor
in the May 2011 release of the NCBI 1000 Genomes sequencing project, which included
1094 subjects, including 381 of European descent.11
Given the importance and specificity of HOXB13 in prostate biology, we sought to further
characterize this mutation. DNA samples from family members from each of these four
pedigrees were sequenced to identify carriers of the HOXB13 G84E mutation.
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Cosegregation of the mutation with disease was observed in all 18 affected men with
available DNA in the four families (Fig. 1).
HOXB13 G84E MUTATION
To further assess HOXB13 G84E as a prostate-cancer susceptibility allele, we studied
several additional populations of European descent with a total of 5083 unrelated case
subjects (see Table 2 in the Supplementary Appendix for clinical characteristics) and 1401
unrelated control subjects. The case subjects included a cohort of 1130 patients with early-
onset or familial prostate cancer from the Prostate Cancer Genetics Project,5,12,13 161
patients with hereditary prostate cancer from Johns Hopkins University,14 a series of 3499
men with localized prostate cancer who were treated with radical prostatectomy at Johns
Hopkins Hospital,15 and 293 men who were treated for advanced prostate cancer at Johns
Hopkins Hospital; the control population of 1401 men were found to have no prostate cancer
during screening.15 Among men in the latter screening group, the G84E mutation was found
in only 1 man, resulting in a carrier-frequency estimate of 0.1%. We did not identify any
homozygous carriers among either case or control subjects.
Overall, men with prostate cancer were significantly more likely to carry the HOXB13
G84E allele (carrier frequency, 1.4%) than were those without prostate cancer (carrier
frequency, 0.1%) (P = 8.5×10−7; odds ratio, 20.1; 95% confidence interval [CI], 3.5 to
803.3) (Table 1). The carrier frequency varied as a function of age at diagnosis and family
history, with the highest rates among men with both a positive family history and early
diagnosis (≤55 years of age) (Table 2, and Table 3 in the Supplementary Appendix). The
carrier frequency in this group (3.1%) was significantly higher than in men with early-on-set
prostate cancer who did not have a family history of the disease (1.0%, P = 0.002) or in men
with a family history in whom prostate cancer was diagnosed after the age of 55 years
(1.2%, P = 0.004) (Table 2). The lowest carrier frequency was observed in men in whom
prostate cancer was diagnosed after the age of 55 years and who did not have a family
history, although this frequency was still higher than in control subjects (0.6%; odds ratio,
8.7; 95% CI, 1.2 to 381.3; P = 0.02) (Table 3 in the Supplementary Appendix). Carrier
frequencies in men with early-onset prostate cancer or those who had a family history were
similar in findings from both the Prostate Cancer Genetics Project and Johns Hopkins
University (data not shown). Results were slightly more significant but odds ratios were
attenuated for comparisons with data from an expanded control population, including
subjects from the Exome Sequencing Project and HapMap (Table 1, and Table 3 in the
Supplementary Appendix).
G84E carriers were significantly younger than noncarriers (52.9 vs. 57.1 years, P =
7.4×10−7) (Table 4 in the Supplementary Appendix). On the basis of clinical data collected
for patients who had undergone radical prostatectomy at the Prostate Cancer Genetics
Project and Johns Hopkins University, we found no evidence supporting significant
differences in Gleason grade between G84E carriers and noncarriers before or after
accounting for the age at diagnosis (Table 4 in the Supplementary Appendix). The G84E
mutation was found in 6 of 293 men (2.0%) who were being treated for metastatic disease.
Finally, we did not identify any additional G84E carriers among 84 unrelated subjects of
African descent with prostate cancer (i.e., unrelated to the 7 subjects of African descent who
were included in the initial sequencing data set) (see the Supplementary Appendix).
ADDITIONAL NOVEL NONSYNONYMOUS HOXB13 MUTATIONS
In the initial targeted sequencing study of 94 families with hereditary prostate cancer, 1
proband from an African-American family was observed to have a novel HOXB13 missense
mutation (transversion c.685C→G), resulting in the substitution of glycine for arginine at
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position 229 (R229G). The same mutation was detected in the patient’s 2 brothers with
prostate cancer. To search for additional HOXB13 variants that were not observed in the
original sequence analysis, we sequenced both exons of HOXB13 in additional men of
European and African descent from the Prostate Cancer Genetics Project and Johns Hopkins
University. A novel substitution of cysteine for glycine at codon 216 (transversion c.
646G→T, p.G216C) was found in an African-Caribbean family. This mutation was present
in both subjects with prostate cancer (2 half-brothers) for whom DNA was available. Neither
the R229G nor the G216C mutation was observed in approximately 1100 African-American
subjects in the Exome Sequencing Project.
HOXB13 was also sequenced in eight available prostate-cancer cell lines (LNCaP, PC3,
DU145, CRW22Rv1, E006AA, VCaP, MDAPCa2b, and LAPC4).16 LNCaP and LAPC4,
both androgen-sensitive human prostate adenocarcinoma cell lines, were found to have
nonsynonymous mutations: substitution of proline for leucine at codon 144 (transition c.
431T→C, L144P) in LNCaP and aspartic acid for tyrosine at codon 88 (transversion c.
262T→G, p.Y88D) in LAPC4. Neither missense mutation was observed in sequencing of
the 94 probands or the database of the Exome Sequencing Project, although a lack of
available germline DNA for these cell lines precluded the determination of a definitive
origin for these changes as somatic or germline.
The locations of the HOXB13 G84E mutation and the four additional rare HOXB13
mutations are shown in Figure 2. All the changes are in highly conserved functional domains
of HOXB13 and are predicted to be damaging to protein function on the Sorting Intolerant
from Tolerant (SIFT)17 or PolyPhen18 algorithms. The G84E and the Y88D mutations are
located in the same non-homeobox domain that was previously shown to mediate the
binding of HOX13 paralogues (including HOXB13) to the MEIS family of HOX cofactor
proteins.19 The L144P change is in the second of two MEIS-binding domains. Both
mutations that were found in subjects of African descent, R229G and G216C, reside in the
N-terminal portion of the homeobox domain, and both changes affect highly conserved
amino acid residues.
DISCUSSION
Targeted sequencing of exons in 202 genes on chromosome 17q21-22 resulted in the
identification of a recurrent mutation, G84E in HOXB13, in four probands of families with a
history of prostate cancer. Analysis of additional case and control subjects revealed that this
variant was associated with prostate-cancer risk and, in particular, early-onset and hereditary
prostate cancer. The identification of several additional rare missense HOXB13 variants
(Y88D, L144P, G216C, and R229G) further implicates HOXB13 in prostate carcinogenesis.
These rare HOXB13 variants appear to be independent of chromosome 17q risk alleles that
have previously been identified in genomewide association studies (see the Supplementary
Appendix).20,21
The HOX genes are a subfamily of the homeobox superfamily of transcription factors
characterized by a highly conserved DNA-binding domain, or homeodomain. In humans,
there are four HOX clusters, with each spanning approximately 200 kb on chromosomes 7
(HOXA), 17 (HOXB), 12 (HOXC), and 2 (HOXD). The combination of coordinated HOX
expression provides a so-called HOX code that is essential for the pattern formation of the
animal body.22 The genes within each HOX cluster are expressed temporally during
development; 3′ genes are expressed early in anterior and proximal regions, whereas 5′
genes are expressed late in posterior and distal regions.23 HOX genes in paralogue group 13
are members of the abdominal B subfamily of such genes, which have posterior domains of
expression, including in the developing urogenital system in vertebrates. Whereas multiple
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HOX13 paralogues are expressed during embryonic development of the prostate, HOXB13
maintains a high expression level into adulthood in normal prostate and, to a lesser level, in
distal colon.
In a study by Economides et al.,24 mice that had been generated from embryonic stem cells
with targeted disruption in HOXB13 had overgrowth of structures arising from the tail bud,
including the spinal cord and tail vertebrae, with decreased apoptosis proposed as a possible
mechanism. Further characterization of these animals showed subtle but definitive, lobe-
specific abnormalities of the prostate gland but without evidence of preneoplastic lesions.25
The mechanisms by which the HOXB13 G84E mutation might act to promote prostate
carcinogenesis are unknown. One clue may be provided by the location of this change in a
conserved domain of the HOXB13 protein that has been shown to mediate binding to
members of the MEIS protein family. This binding is thought to modulate the interaction of
HOX proteins with specific DNA or other proteins and thus finetune HOX function. MEIS
expression has been implicated in collaboration with HOX genes in the development of
leukemia.26 Understanding how G84E affects the interaction between HOXB13 and the
MEIS proteins and what effect this has on HOXB13–MEIS function is an obvious area for
future research.
Several studies have examined the role of HOXB13 in normal and cancerous prostate
biology, although substantially different conclusions have been reached, with HOXB13
being implicated as both a tumor suppressor and an oncogene in prostate and other cancers.
For example, the growth of the prostate-cancer cell line LNCaP has been shown to be
suppressed by both experimental overexpression of HOXB13 by transfection and by
reduction of endogenous HOXB13 expression by RNA interference.27 It is clear that
HOXB13 physically interacts with the androgen receptor, one of the most important growth
and differentiation regulators in normal and cancerous prostate biology.27,28 Direct
experimentation with the G84E allele will be necessary to determine its effect on cell
development and differentiation in prostate cancer.
The recurrent nature of the G84E change and a reported lack of any truncating mutations in
HOXB13 in patients with prostate cancer suggest a carcinogenic mechanism that is more
consistent with a gain of function (oncogene) than with a loss of function (tumor-suppressor
gene). Both deletions29 and amplifications30 of 17q21 have been described in prostate-
cancer specimens. However, such analyses need to be performed in tumors from known
HOXB13 G84E carriers. Multiple studies have shown the prostate specificity of high-level
HOXB13 expression, and this expression appears to be maintained in the formation and
progression of prostate cancer.31 Our preliminary analyses indicate that tumors in G84E
carriers continue to express HOXB13 and maintain the mutant allele (Fig. 3, and Fig. 1 in
the Supplementary Appendix).
In summary, we have used linkage analysis in combination with targeted massively parallel
sequencing to identify a recurrent mutation in HOXB13 that is associated with early-onset
and hereditary prostate cancer. From a clinical perspective, testing for germline mutations in
BRCA1/2 is recommended in some families, since mutations in these breast-cancer–
susceptibility genes are associated with elevations in the risk of prostate cancer, particularly
for BRCA2.32,33 However, neither of these genes has been shown to contribute to hereditary
prostate cancer.34,35 HOXB13 G84E is associated with a significantly increased risk of
hereditary prostate cancer. This work suggests that future DNA sequencing studies using
next-generation technology and study populations enriched for genetic influence (as
evidenced by an early age at onset and positive family history) may identify additional rare
variants that will contribute to familial clustering of prostate cancer. Although HOXB13
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mutations will be identified in a minority of men with prostate cancer, rare genetic lesions
can identify pathways that are found to be abnormal in more common, sporadic cases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Pedigrees of Four Subjects with the HOXB13 G84E Mutation on Initial Targeted
Sequencing
The proband who was selected for sequencing is indicated by the arrow in each pedigree.
The remaining symbols are described in the key. Squares indicate male sex, and circles
female sex. Ages of subjects, rounded to the nearest 5-year interval, are shown under the
symbols. A slash through the symbol indicates that the subject is deceased. Two subjects in
two families, Family 1 from the University of Michigan Prostate Cancer Genetics Project
(UM) and Family 1 from Johns Hopkins University (JHU), who were inferred to be obligate
carriers of the HOXB13 G84E mutation, died from prostate cancer. The unaffected G84E
carrier in JHU Family 1 was 70 years of age at last contact.
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Figure 2. Structure of HOXB13
The HOXB13 gene is the most 5′ member of the HOXB gene cluster on chromosome
17q21-22. The locations of the five missense mutations are indicated in the two exons of
HOXB13. The homeodomain region and MEIS interacting domains are indicated. CDS
denotes coding sequences, and UTR untranslated regions.
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Figure 3. DNA Sequence Chromatograms Obtained from Normal Prostate and Prostate-Cancer
Tissue from a Heterozygous Carrier of the HOXB13 G84E Variant, with Associated Histologic
Findings
Wild-type and mutant DNA are present in both normal prostate tissue and prostate-cancer
tissue from HOXB13 G84E carriers. For this experiment, DNA was extracted from sections
of paraffin-embedded blocks of tissue obtained during a radical prostatectomy performed in
a patient who was heterozygous for the HOXB13 G84E variant. The blocks were selected
and trimmed to contain either normal or tumor tissue, as shown on hematoxylin and eosin
staining (at left), and were subjected to Sanger sequencing. The chromatograms (at right)
show the presence of both wild-type (GGA) and mutant (GAA) alleles at codon 84 in
normal prostate tissue (middle) and the maintenance of both alleles in the matched sample of
prostate tumor tissue (bottom). The top chromatogram is a homozygous wild-type sequence
from a subject without the G84E mutation. The genome position that is shown (44,160,704)
is based on the National Center for Biotechnology Information database, build 36 (hg18).
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Table 1











Pool of Control Subjects ‡
Odds Ratio P Value Odds Ratio P Value
no. %
UM-PCGP and Johns Hopkins
University
All subjects§ 72 5011 1.4 20.1 8.5×10−7 9.5 2.4×10−9
Subjects from 85 sequenced families
with
 hereditary prostate cancer
4 81 4.7 68.4 4.8×10−5 32.6 5.4×10−5
UM-PCGP
Subjects with early-onset or hereditary
 prostate cancer§
26 1104 2.3 33.0 1.0×10−8 15.6 1.3×10−10
Johns Hopkins University
Subjects with hereditary prostate
cancer§ and
 those undergoing prostatectomy or
other
 oncologic therapy
46 3907 1.2 16.5 1.6×10−5 7.8 6.0×10−7
Control subjects
Johns Hopkins University 1 1400 0.1 NA NA NA NA
Exome Sequencing Project plus CEU
HapMap
3 1258 0.2 NA NA NA NA
*
The HOXB13 G84E mutation was detected by means of both direct sequencing and high-throughput genotyping approaches. CEU denotes Centre
d’Etude du Polymorphisme Humain from Utah, NA not applicable, and UM-PCGP University of Michigan Prostate Cancer Genetics Project.
†
Case subjects were compared with 1401 control subjects at Johns Hopkins University.
‡
Case subjects were compared with 1401 control subjects at Johns Hopkins University plus 1233 subjects in the Exome Sequencing Project and 28
unrelated genotyped subjects from the CEU HapMap.
§
This category includes unrelated subjects with prostate cancer, excluding the 85 families of European descent used for discovery. The youngest
available subject with prostate cancer was selected from families that had more than one subject with the disease.
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Table 2
Frequency of HOXB13 G84E Carriers in Subjects of European Descent with Prostate Cancer, According to











Family history of prostate cancer
  Positive 45 2019 2.2 Negative family history 2.8 (1.6–5.1) 1.2×10−4
  Negative 19 2391 0.8 NA NA NA
Age at prostate-cancer diagnosis
 ≤55 yr 46 2084 2.2 Age at diagnosis, >55 yr 2.7 (1.6–4.7) 1.1×10−4
 >55 yr 22 2681 0.8 NA NA NA
Positive family history













 Age at diagnosis, >55 yr 9 1447 0.6 NA NA NA
*
Included are 4474 subjects with data on family history and 4833 subjects with data on the age at diagnosis from the University of Michigan
Prostate Cancer Genetics Project and Johns Hopkins University.
†
Additional comparisons are as follows: Among subjects with a positive family history, the odds ratio for the presence of the HOXB13 G84E
mutation among those with an early-onset diagnosis (≤55 years), as compared with a later-onset diagnosis (>55 years), was 2.6 (95% CI, 1.3 to 5.6;
P = 0.004). Among subjects with early-onset disease, the odds ratio among those with a positive family history, as compared with a negative family
history, was 3.0 (95% CI, 1.4 to 6.8; P = 0.002). NA denotes not applicable.
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